BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22950955)

  • 1. Drug treatment of metabolic syndrome.
    Altabas V
    Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.
    Srikanth S; Deedwania P
    Curr Hypertens Rep; 2016 Oct; 18(10):76. PubMed ID: 27730495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for the metabolic syndrome.
    Swislocki AL; Siegel D; Jialal I
    Curr Vasc Pharmacol; 2012 Mar; 10(2):187-205. PubMed ID: 22022773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A patient with cardiovascular risk factors and comorbidities: integration of indications and contra-indications in pharmacotherapy].
    Scheen AJ
    Rev Med Liege; 2010; 65(7-8):476-81. PubMed ID: 20857708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome.
    Robins SJ
    Curr Cardiol Rep; 2005 Nov; 7(6):457-64. PubMed ID: 16256016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
    Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
    Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance and the metabolic syndrome.
    Lann D; Gallagher E; Leroith D
    Minerva Med; 2008 Jun; 99(3):253-62. PubMed ID: 18497723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic syndrome and the role of the polypill in the prevention of its complications].
    Rosolová H
    Vnitr Lek; 2017; 63(10):712-716. PubMed ID: 29127755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Menopause and metabolic syndrome].
    Meirelles RM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):91-6. PubMed ID: 24830585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing cardiovascular disease and diabetes: a call to action from the ADA and AHA.
    Wyne KL
    J Cardiometab Syndr; 2006; 1(3):220-1. PubMed ID: 17679801
    [No Abstract]   [Full Text] [Related]  

  • 14. The metabolic basis of atherogenic dyslipidemia.
    Vinik AI
    Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
    Greenberg AS
    J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
    Nakajima K
    Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.
    Gonzalez GL; Manrique CM; Sowers JR
    J Cardiometab Syndr; 2006; 1(3):178-83. PubMed ID: 17679817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical risk in patients with metabolic syndrome: focus on lipids and hypertension.
    Watson K
    Curr Cardiol Rep; 2006 Nov; 8(6):433-8. PubMed ID: 17059795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nutrition and metabolic syndrome].
    Matía Martín P; Lecumberri Pascual E; Calle Pascual AL
    Rev Esp Salud Publica; 2007; 81(5):489-505. PubMed ID: 18274353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.